AstraZeneca (LON:AZN) Upgraded to Hold by Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca (LON:AZN) to a hold rating in a report published on Monday morning, Marketbeat.com reports.

A number of other research firms have also weighed in on AZN. JPMorgan Chase & Co. reaffirmed an overweight rating on shares of AstraZeneca in a research note on Thursday, April 4th. BMO Capital Markets reissued an outperform rating on shares of AstraZeneca in a research note on Monday, February 12th. Berenberg Bank reissued a buy rating on shares of AstraZeneca in a research note on Wednesday, March 13th. UBS Group lowered their price objective on AstraZeneca from £107 ($133.20) to GBX 9,900 ($123.24) and set a sell rating for the company in a research note on Monday, February 12th. Finally, Jefferies Financial Group reaffirmed a hold rating and issued a £110 ($136.94) price objective on shares of AstraZeneca in a research note on Friday, February 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, AstraZeneca has a consensus rating of Moderate Buy and an average price target of £115.43 ($143.69).

AstraZeneca Stock Up 0.5 %

AstraZeneca stock opened at £109.14 ($135.86) on Monday. The stock has a market cap of £169.17 billion, a PE ratio of 3,601.98, a price-to-earnings-growth ratio of 0.89 and a beta of 0.19. The company has a debt-to-equity ratio of 75.70, a quick ratio of 0.59 and a current ratio of 0.82. AstraZeneca has a one year low of GBX 9,461 ($117.78) and a one year high of £123.48 ($153.72). The stock has a fifty day moving average of £103.71 and a 200 day moving average of £104.29.

AstraZeneca Increases Dividend

The firm also recently declared a dividend, which was paid on Monday, March 25th. Investors of record on Thursday, February 22nd were issued a GBX 156 ($1.94) dividend. This is a boost from AstraZeneca’s previous dividend of $71.80. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a yield of 1.49%. AstraZeneca’s dividend payout ratio is presently 7,524.75%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.